Ross S - Search Results

1

Genetic markers of inflammation and their role in cardiovascular disease.

Raman K, Chong M, Akhtar-Danesh GG, D'Mello M, Hasso R, Ross S, Xu F, Paré G. Raman K, et al. Among authors: ross s. Can J Cardiol. 2013 Jan;29(1):67-74. doi: 10.1016/j.cjca.2012.06.025. Epub 2012 Sep 19. Can J Cardiol. 2013. PMID: 22999193 Review.

2

Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.

Paré G, Ross S, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Fox KA, Eikelboom JW. Paré G, et al. Among authors: ross s. Circ Cardiovasc Genet. 2012 Apr 1;5(2):250-6. doi: 10.1161/CIRCGENETICS.111.961417. Epub 2012 Feb 24. Circ Cardiovasc Genet. 2012. PMID: 22368149 Clinical Trial.

3

Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.

Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, Anand SS, Zuvich RL, Bradford Y, Ross S, Nakamura Y, Ritchie M, Brown NJ. Pare G, et al. Among authors: ross s. Pharmacogenet Genomics. 2013 Sep;23(9):470-8. doi: 10.1097/FPC.0b013e328363c137. Pharmacogenet Genomics. 2013. PMID: 23838604 Free PMC article. Clinical Trial.

4

Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.

Ross S, Paré G. Ross S, et al. Pharmacogenomics. 2013 Oct;14(13):1565-72. doi: 10.2217/pgs.13.149. Pharmacogenomics. 2013. PMID: 24088127 Review.

5

Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009.

Joseph PG, Pare G, Ross S, Roberts R, Anand SS. Joseph PG, et al. Among authors: ross s. Clin Cardiol. 2014 Jan;37(1):48-56. doi: 10.1002/clc.22200. Epub 2013 Sep 17. Clin Cardiol. 2014. PMID: 24105892 Free PMC article.

6

Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues.

Ross S, Anand SS, Joseph P, Paré G. Ross S, et al. JRSM Cardiovasc Dis. 2012 Apr 5;1(1):cvd.2012.012001. doi: 10.1258/cvd.2012.012001. JRSM Cardiovasc Dis. 2012. PMID: 24175062 Free PMC article. Review.

7

Association of cyclooxygenase-2 genetic variant with cardiovascular disease.

Ross S, Eikelboom J, Anand SS, Eriksson N, Gerstein HC, Mehta S, Connolly SJ, Rose L, Ridker PM, Wallentin L, Chasman DI, Yusuf S, Paré G. Ross S, et al. Eur Heart J. 2014 Sep 1;35(33):2242-8a. doi: 10.1093/eurheartj/ehu168. Epub 2014 May 5. Eur Heart J. 2014. PMID: 24796340 Free PMC article.

8

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.

Merali Z, Ross S, Paré G. Merali Z, et al. Among authors: ross s. Drug Metabol Drug Interact. 2014;29(3):143-51. doi: 10.1515/dmdi-2014-0009. Drug Metabol Drug Interact. 2014. PMID: 24988246 Review.

9

Association between shortened leukocyte telomere length and cardiometabolic outcomes: systematic review and meta-analysis.

D'Mello MJ, Ross SA, Briel M, Anand SS, Gerstein H, Paré G. D'Mello MJ, et al. Among authors: ross sa. Circ Cardiovasc Genet. 2015 Feb;8(1):82-90. doi: 10.1161/CIRCGENETICS.113.000485. Epub 2014 Nov 18. Circ Cardiovasc Genet. 2015. PMID: 25406241 Review.

10

Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease.

Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Paré G. Ross S, et al. Eur Heart J. 2015 Jun 14;36(23):1454-62. doi: 10.1093/eurheartj/ehv083. Epub 2015 Mar 29. Eur Heart J. 2015. PMID: 25825043

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,041 results

Search Page